Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.

The efficacy of ten daily injections of 500 or 500,000 U of recombinant interleukin 2 (IL-2) day-1 given 1.5 cm from the insertion of the sternocleidomastoid muscle on the mastoid was evaluated in 31 patients with recurrent head and neck squamous cell carcinoma. No toxic effects were noted. One comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortesina, G., De Stefani, A., Galeazzi, E., Cavallo, G. P., Badellino, F., Margarino, G., Jemma, C., Forni, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968846/
https://www.ncbi.nlm.nih.gov/pubmed/8123489
_version_ 1782134829483032576
author Cortesina, G.
De Stefani, A.
Galeazzi, E.
Cavallo, G. P.
Badellino, F.
Margarino, G.
Jemma, C.
Forni, G.
author_facet Cortesina, G.
De Stefani, A.
Galeazzi, E.
Cavallo, G. P.
Badellino, F.
Margarino, G.
Jemma, C.
Forni, G.
author_sort Cortesina, G.
collection PubMed
description The efficacy of ten daily injections of 500 or 500,000 U of recombinant interleukin 2 (IL-2) day-1 given 1.5 cm from the insertion of the sternocleidomastoid muscle on the mastoid was evaluated in 31 patients with recurrent head and neck squamous cell carcinoma. No toxic effects were noted. One complete response (CR) and three partial responses (PRs) were observed in the 16 patients who received 500 U of IL-2, whereas the higher dose was not effective. The CR was recorded in one of the seven patients with a oropharyngeal recurrence. Partial responses were obtained in 1/5 patients with hypopharyngeal recurrences, in 1/5 patients with oral cavity recurrences and 1/7 patients with laryngeal recurrences. The duration of the responses was 3-5 months and additional courses of ten injections of IL-2 had no further effect. IMAGES:
format Text
id pubmed-1968846
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19688462009-09-10 Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Cortesina, G. De Stefani, A. Galeazzi, E. Cavallo, G. P. Badellino, F. Margarino, G. Jemma, C. Forni, G. Br J Cancer Research Article The efficacy of ten daily injections of 500 or 500,000 U of recombinant interleukin 2 (IL-2) day-1 given 1.5 cm from the insertion of the sternocleidomastoid muscle on the mastoid was evaluated in 31 patients with recurrent head and neck squamous cell carcinoma. No toxic effects were noted. One complete response (CR) and three partial responses (PRs) were observed in the 16 patients who received 500 U of IL-2, whereas the higher dose was not effective. The CR was recorded in one of the seven patients with a oropharyngeal recurrence. Partial responses were obtained in 1/5 patients with hypopharyngeal recurrences, in 1/5 patients with oral cavity recurrences and 1/7 patients with laryngeal recurrences. The duration of the responses was 3-5 months and additional courses of ten injections of IL-2 had no further effect. IMAGES: Nature Publishing Group 1994-03 /pmc/articles/PMC1968846/ /pubmed/8123489 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Cortesina, G.
De Stefani, A.
Galeazzi, E.
Cavallo, G. P.
Badellino, F.
Margarino, G.
Jemma, C.
Forni, G.
Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.
title Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.
title_full Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.
title_fullStr Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.
title_full_unstemmed Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.
title_short Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.
title_sort temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968846/
https://www.ncbi.nlm.nih.gov/pubmed/8123489
work_keys_str_mv AT cortesinag temporaryregressionofrecurrentsquamouscellcarcinomaoftheheadandneckisachievedwithalowbutnotwithahighdoseofrecombinantinterleukin2injectedperilymphatically
AT destefania temporaryregressionofrecurrentsquamouscellcarcinomaoftheheadandneckisachievedwithalowbutnotwithahighdoseofrecombinantinterleukin2injectedperilymphatically
AT galeazzie temporaryregressionofrecurrentsquamouscellcarcinomaoftheheadandneckisachievedwithalowbutnotwithahighdoseofrecombinantinterleukin2injectedperilymphatically
AT cavallogp temporaryregressionofrecurrentsquamouscellcarcinomaoftheheadandneckisachievedwithalowbutnotwithahighdoseofrecombinantinterleukin2injectedperilymphatically
AT badellinof temporaryregressionofrecurrentsquamouscellcarcinomaoftheheadandneckisachievedwithalowbutnotwithahighdoseofrecombinantinterleukin2injectedperilymphatically
AT margarinog temporaryregressionofrecurrentsquamouscellcarcinomaoftheheadandneckisachievedwithalowbutnotwithahighdoseofrecombinantinterleukin2injectedperilymphatically
AT jemmac temporaryregressionofrecurrentsquamouscellcarcinomaoftheheadandneckisachievedwithalowbutnotwithahighdoseofrecombinantinterleukin2injectedperilymphatically
AT fornig temporaryregressionofrecurrentsquamouscellcarcinomaoftheheadandneckisachievedwithalowbutnotwithahighdoseofrecombinantinterleukin2injectedperilymphatically

Ejemplares similares